Current Controversy on Platelets and Patent Ductus Arteriosus Closure in Preterm Infants
- PMID: 33718298
- PMCID: PMC7946843
- DOI: 10.3389/fped.2021.612242
Current Controversy on Platelets and Patent Ductus Arteriosus Closure in Preterm Infants
Abstract
Platelets are critically involved in murine patent ductus arteriosus (PDA) closure. To date, the clinical significance of these findings in human preterm infants with PDA is still controversial. We discuss the available study data on the role of platelets for PDA closure in preterm infants: Several mostly retrospective studies have yielded conflicting results on whether thrombocytopenia contributes to failed spontaneous ductal closure. The same applies to investigations on the role of thrombocytopenia as a risk factor for unsuccessful ductus arteriosus closure by pharmacological treatment with cyclooxygenase inhibitors. Nonetheless, recent meta-analyses have concluded that thrombocytopenia constitutes an independent risk factor for both failed spontaneous and pharmacological PDA closure in preterm infants. However, the available investigations differ in regard to patient characteristics, diagnostic strategies, and treatment protocols. Several studies suggest that impaired platelet function rather than platelet number is critically involved in failure of ductus arteriosus closure in the preterm infant. A recent randomized-controlled trial on platelet transfusions in preterm infants with PDA failed to show any benefit for liberal vs. restrictive transfusion thresholds on PDA closure rates. Importantly, liberal transfusions were associated with an increased rate of intraventricular hemorrhage, and thus should be avoided. In conclusion, the available evidence suggests that thrombocytopenia and platelet dysfunction contribute to failure of spontaneous and pharmacological PDA closure in preterm infants. However, these platelet effects on PDA seem to be of only moderate clinical significance. Furthermore, platelet transfusions in thrombocytopenic preterm infants in order to facilitate PDA closure appear to cause more harm than good.
Keywords: hemodynamics; patent ductus arteriosus; platelets; thrombocytopenia; very low birth weight.
Copyright © 2021 Sallmon, Timme, Atasay, Erdeve, Hansmann, Singh, Weber and Shelton.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Platelets and ductus arteriosus closure in neonates.Semin Perinatol. 2023 Mar;47(2):151719. doi: 10.1016/j.semperi.2023.151719. Epub 2023 Mar 1. Semin Perinatol. 2023. PMID: 36925318 Clinical Trial.
-
Platelet Transfusion for PDA Closure in Preterm Infants: A Randomized Controlled Trial.Pediatrics. 2019 May;143(5):e20182565. doi: 10.1542/peds.2018-2565. Epub 2019 Apr 2. Pediatrics. 2019. PMID: 30940676 Clinical Trial.
-
Thrombocytopenia in the first 24 hours after birth and incidence of patent ductus arteriosus.Pediatrics. 2012 Sep;130(3):e623-30. doi: 10.1542/peds.2012-0499. Epub 2012 Aug 6. Pediatrics. 2012. PMID: 22869835
-
Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants.Cochrane Database Syst Rev. 2020 Jan 27;1(1):CD010061. doi: 10.1002/14651858.CD010061.pub4. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2022 Dec 15;12:CD010061. doi: 10.1002/14651858.CD010061.pub5. PMID: 31985831 Free PMC article. Updated.
-
Interventions for patent ductus arteriosus (PDA) in preterm infants: an overview of Cochrane Systematic Reviews.Cochrane Database Syst Rev. 2023 Apr 11;4(4):CD013588. doi: 10.1002/14651858.CD013588.pub2. Cochrane Database Syst Rev. 2023. PMID: 37039501 Free PMC article. Review.
Cited by
-
Systemic Inflammatory Indices as New Biomarkers for Hemodynamically Significant Ductus Arteriosus.Arq Bras Cardiol. 2024 Nov;121(11):e20240211. doi: 10.36660/abc.20240211. Arq Bras Cardiol. 2024. PMID: 39630813 Free PMC article. English, Portuguese.
-
Platelet Count Might Be Associated With the Closure of Hemodynamically Significant Patent Ductus Arteriosus.Front Pediatr. 2021 Oct 11;9:729461. doi: 10.3389/fped.2021.729461. eCollection 2021. Front Pediatr. 2021. PMID: 34708010 Free PMC article.
-
Mouse models of patent ductus arteriosus (PDA) and their relevance for human PDA.Dev Dyn. 2022 Mar;251(3):424-443. doi: 10.1002/dvdy.408. Epub 2021 Aug 14. Dev Dyn. 2022. PMID: 34350653 Free PMC article. Review.
-
An Update on Patent Ductus Arteriosus and What is Coming Next.Turk Arch Pediatr. 2022 Mar;57(2):118-131. doi: 10.5152/TurkArchPediatr.2022.21361. Turk Arch Pediatr. 2022. PMID: 35383006 Free PMC article.
-
Evaluation of platelet function by Total Thrombus-Formation Analysis System (T-TAS®01) in term and preterm infants and its relationship with patent ductus arteriosus. A prospective observational pilot study.Blood Transfus. 2025 May-Jun;23(3):255-265. doi: 10.2450/BloodTransfus.765. Epub 2024 Oct 25. Blood Transfus. 2025. PMID: 39621887 Free PMC article.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources